Our look is new. Our purpose is the same. Learn more about our brand evolution.
The DUX4 gene in FSH muscular dystrophy is typically described as a rogue actor, a genetic oddball that is never supposed to be active in adult muscle, and is rendered […]
Watch the videos here. The University of Rochester Fields Center for FSHD Research has posted a summary and videos from the 6th annual FSHD Family Day Conference held on April […]
by Jim Albert, Eldersburg, MD The FSHD Clinical Trial Research Network (CTRN) is currently recruiting up to 160 FSHD patients across the seven CTRN sites to participate in a study called […]
by Amanda Hill, Denver, Colorado FSHD clinical researchers recently published what may soon become a standard battery of assessments for use in clinical trials, an exciting and essential milestone for […]
The Massachusetts-based biotech, Acceleron Pharma, issued a press release this morning with some encouraging news for FSH muscular dystrophy patients about its experimental drug, ACE-083 (see related story). Here is […]
